Hypoxia and long noncoding RNA

缺氧和长非编码RNA

基本信息

批准号：
8752852
负责人：
Nobuaki Kikyo
金额：
$ 19.84万
依托单位：
UNIVERSITY OF MINNESOTA
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-07-01 至 2016-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8752852
关键词：
6-Phosphofructo-2-kinase Antibodies Automobile Driving Binding Binding Sites Biological Markers Breast Cancer Cell Cancer Patient Cancer cell line Cell Culture Techniques Cell Proliferation Cells Chromatin Chromatin Structure Complex DNA Binding Deposition Disadvantaged Energy Metabolism Enzymes Family Gene Expression Regulation Gene Targeting Genes Genetic Transcription Glucose Glycolysis Growth Factor Hexokinase 2 Histones Hypoxia Hypoxia Inducible Factor Link Maps Messenger RNA Metabolic Metabolic Pathway Molecular Chaperones Names Neoplasm Metastasis Oxidative Phosphorylation Pharmaceutical Preparations Proteins RNA Binding RNA Sequences RNA Splicing Reactive Oxygen Species Recruitment Activity Regenerative Medicine Regulation Reporting Resistance Ribosomal RNA Role Signal Transduction Testing Transfer RNA Translations Undifferentiated Untranslated RNA Up-Regulation Variant angiogenesis base cancer cell cancer initiation cancer therapy cancer type chemotherapy chromatin immunoprecipitation chromatin protein design dimer embryonic stem cell genome-wide glucose metabolism human embryonic stem cell hypoxia inducible factor 1 improved innovation knock-down lactate dehydrogenase A new therapeutic target novel outcome forecast pluripotency prevent promoter public health relevance response screening therapeutic target therapy resistant transcription factor tumor tumor progression vpr Genes

项目摘要

DESCRIPTION (provided by applicant): Cancer cells express hypoxia-inducible factors (HIFs) in hypovascularized regions inside a tumor mass in response to hypoxia. HIFs activate more than 800 genes including those involved in angiogenesis, glycolysis, and growth factor signaling, which collectively facilitate cancer progression and metastasis. Indeed, increased expression of HIFs is an indicator for poor prognosis of cancer patients. In addition, embryonic stem cells (ESCs) maintain an undifferentiated state more efficiently in hypoxia than in normoxia. Therefore, it is important to understand the functions and regulation of HIFs for cancer therapy and regenerative medicine. The current project will identify and characterize long noncoding RNAs (lncRNAs) that are bound to HIF-1 in human breast cancer cells and embryonic stem cells (ESCs) cultured in hypoxia. LncRNAs are defined as RNAs that are longer than 200 bases and do not encode mRNA, rRNA, or tRNA. Chromatin immunoprecipitation and RNA sequencing were used to identify novel HIF-1-bound lncRNAs (collectively called R-HIFs) that have been mapped closely to genes encoding glycolysis enzymes. Cancer cells and ESCs use glycolysis as a primary metabolic pathway of glucose rather than oxidative phosphorylation in normoxia and this tendency is enhanced by HIFs in hypoxia. Enhanced glycolysis has an advantage of producing more metabolic intermediates necessary for rapid cell proliferation. Thus, the regulation of glycolytic enzymes by lncRNAs can serve as a novel target for cancer therapy. Currently virtually nothing is known about the involvement of lncRNAs in hypoxia or glycolysis. It was hypothesized that HIF-1 uses lncRNAs as novel coactivators to regulate its target genes, including glycolysis genes, in hypoxia and thereby promotes proliferation of breast cancer cells and ESCs. The following 3 aims have been proposed to test this hypothesis. Aim 1 is designed to identify direct target genes of an R-HIF by screening of its DNA binding sites and by identification of genes whose expression level is altered by the knockdown of the R-HIF. In Aim 2 the roles of other R-HIFs in hypoxic gene regulation will be determined by the combination of knockdown, analysis of their genome-wide binding sites, and identification of associated chromatin proteins. In Aim 3 the roles of the R-HIFs in increased glycolysis and decreased oxidative phosphorylation in hypoxic cancer cells and ESCs will be determined through the analysis of energy and glucose metabolism. These studies are expected to establish lncRNAs as a novel entity essential for the regulation of glycolytic genes by HIF-1 in hypoxia.

描述（由申请人提供）：癌细胞在肿瘤质量中表达缺氧区域中缺氧诱导的因素（HIF），这响应缺氧。 HIF激活了800多个基因，包括参与血管生成，糖酵解和生长因子信号传导，这些基因共同促进了癌症的进展和转移。实际上，HIF的表达增加是癌症患者预后不良的指标。此外，胚胎干细胞（ESC）在缺氧中比在常规赛中更有效地保持未分化状态。因此，重要的是要了解HIF的癌症治疗和再生医学的功能和调节。当前的项目将识别并表征在人类乳腺癌细胞和缺氧中培养的胚胎干细胞（ESC）中与HIF-1的长期非编码RNA（LNCRNA）。 lncRNA被定义为超过200个碱基且不编码mRNA，rRNA或tRNA的RNA。染色质免疫沉淀和RNA测序用于鉴定新型HIF-1结合的LNCRNA（统称称为R-HIFS），这些LNCRNA已与编码编码糖酵解酶的基因映射。癌细胞和ESC使用糖酵解作为葡萄糖的主要代谢途径，而不是常氧化中的氧化磷酸化，而缺氧的HIF可以增强这种趋势。增强的糖酵解具有产生快速细胞增殖所需的代谢中间体的优势。因此，通过LNCRNA对糖酵解酶的调节可以作为癌症治疗的新靶标。目前，对于LNCRNA在缺氧或糖酵解中的参与几乎一无所知。假设HIF-1使用LNCRNA作为新型共激活剂来调节缺氧的靶基因，包括糖酵解基因，从而促进乳腺癌细胞和ESC的增殖。已经提出了以下3个目标来检验这一假设。 AIM 1旨在通过筛选其DNA结合位点以及鉴定其表达水平因R-HIF的敲低而改变的基因来识别R-HIF的直接靶基因。在AIM 2中，其他R-HIF在低氧基因调节中的作用将取决于敲低的结合，其全基因组结合位点的分析以及相关染色质蛋白的鉴定。在AIM 3中，R-HIFS在糖酵解增加和缺氧癌细胞中氧化磷酸化降低中的作用将通过分析能量和葡萄糖代谢来确定。预计这些研究将建立LNCRNA作为HIF-1在缺氧中调节糖酵解基因必不可少的新实体。